ArticleInternational journal of clinical and experimental pathology2025
Bioinformatic analysis of the role of USP22 expression in hepatocellular carcinoma.
Article in International journal of clinical and experimental pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLiver hepatocellular carcinoma (LIHC) is the most prevalent liver malignancy, often diagnosed at advanced stages, and resulting in a poor prognosis for patients. Ubiquitin-specific peptidase 22 (USP22) belongs to the ubiquitin-specific processing proteases (USPs) subfamily and has been identified as a gene signature associated with various cancer types in previous studies. However, the exact role of USP22 in LIHC remains to be fully elucidated.
methodsMultiple online bioinformatics databases were usedto investigate gene expression patterns, prognosis, mutations, and immune infiltration in LIHC patients. The UALCAN database was employed to analyze the gene expression of USP22 and its correlation with clinicopathologic data. The cBioPortal database was used to analyze the mutation status, and the Human Protein Atlas (HPA) database was utilized to illustrate the protein's localization. The STRING and GeneMANIA databases were employed to establish the protein-protein interaction (PPI) network. The GEPIA2 database was used to identify the top 100 genes correlated with USP22 in LIHC, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed using the 'clusterProfiler' R package. The TISIDB database was used to analyze the correlation between the USP22 gene and immune infiltration in LIHC.
resultsUSP22 was upregulated in LIHC, with high levels of USP22 correlating with poor overall survival (OS) (P=0.019) and showing associations with tumor stage, histologic subtype, and TP53 mutant status. Immunohistochemistry data showed that USP22 localized in the nucleus of hepatocytes. Nine proteins, including ATXN7, ENY2, TRRAP, TAF5L, TADA3, TADA1, SUPT3H, SUPT20H, and ATXN7L3, were identified as the hub binding proteins in PPI networks. GO and KEGG enrichment analyses indicated that the genes correlated with USP22 in HCC were involved in histone modification, RNA splicing, and regulation of mRNA metabolic processes and were associated with the Notch signaling pathway, ubiquitin-mediated proteolysis, and the Wnt signaling pathway. Moreover, USP22 expression exhibited a significant negative correlation with immune infiltration by CD8+ T cells, macrophages, monocytes, and NK cells.
conclusionsThe prognostic relevance of USP22 in LIHC was found by leveraging data from multiple databases, providing fresh insight that targeting USP22 may help develop new therapeutic approaches for LIHC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.